Abbott Labs Sells Developed Markets Generics Unit

July 14 (Bloomberg) -- Marshall Sonenshine, chairman and managing partner at Sonenshine Partners, and Jonathan Golub, chief U.S. market strategist at RBC Capital Markets, examine Abbott Laboratories selling its developed markets generic drug unit to Mylan in a deal worth $5.3 Billion and what it means to the current M&A market. They speak on “Bloomberg Surveillance.”
Is Virtual Reality the Next Mega-Trend in Tech?
41:36 - Piper Jaffray's Gene Munster and Canaan Partners' Maha Ibrahim discuss the future of virtual reality with Bloomberg Businessweek's Brad Stone on "Bloomberg West." (Source: Bloomberg)
  • Tech, Financials to Be Rediscovered in 2-3 Years: Lee
  • Week in Review: U.S. GDP Shrinks 0.7% in 1Q
  • Humana Soars as Possible Sale Explored